Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Rating of “Buy” by Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have been given an average recommendation of “Buy” by the eight ratings firms that are covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $81.29.

Several analysts recently issued reports on the stock. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $27.40 on Monday. Structure Therapeutics has a 52 week low of $23.50 and a 52 week high of $62.74. The stock has a 50 day moving average price of $29.21 and a two-hundred day moving average price of $34.92. The stock has a market capitalization of $1.57 billion, a PE ratio of -37.03 and a beta of -2.75.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Wellington Management Group LLP grew its holdings in shares of Structure Therapeutics by 2.9% in the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after acquiring an additional 221,851 shares in the last quarter. FMR LLC boosted its position in Structure Therapeutics by 6.7% in the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after purchasing an additional 383,635 shares during the last quarter. Janus Henderson Group PLC grew its stake in Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after purchasing an additional 602,609 shares during the period. Point72 Asset Management L.P. increased its position in shares of Structure Therapeutics by 196.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock valued at $54,348,000 after purchasing an additional 820,589 shares during the last quarter. Finally, Vestal Point Capital LP raised its stake in shares of Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.